Commercialising research

Our commercialisation team protects and exploits the University’s intellectual property, generated through its research, helping to maximise the economic, commercial and societal impact of that research.

The University places importance on supporting academics through the process of commercialising their research. This is evidenced through the University’s Enterprise Investment Fund (EIF), a significant annual fund which is dedicated to supporting commercialisation projects. Funding is available for staff to de-risk technologies developed at the University, ideally following validation via other internal Proof of Concept funds (e.g. UKRI Impact Acceleration Account (IAA) funding), and provide start-up investment to our spin-out companies.

Through our partnership with the NxNW consortium, our academics can access external accelerator programmes, such as the Innovate UK funded Innovation-to-Commercialisation of University Research (ICURe) Discovery and Explore schemes. 

Our technologies

View some of our latest research and technologies
Two University spin-outs make LCR tech business sector list

Two University spin-outs make prestigious LCR tech business sector list

The Liverpool City Region (LCR) Tech Climbers 2024 list was recently revealed – with two University spin-outs, Atomik AM and Plasma2x Limited, recognised for their achievements.

University of Liverpool ranked as top in the North West for Entrepreneurial Impact

The rankings measure universities’ success at turning their academic achievements into thriving companies
SenseAI software speeds up electron microscopy

SenseAI

Disruptive sub-sampling software from SenseAI speeds up electron microscopy by up to 100x. SenseAI partners with Quantum Detectors to launch at M&M 2023.

ReNewVax one year on

ReNewVax’s leadership team reflect on the company’s first year

Liverpool welcomes Government's announcement of UK spin-out landscape review

HMT announced the findings of an independent review of the UK’s spin-out landscape to identify best practice in turning university research into commercial success.
Future Founders Programme

Future Founders Programme

Supporting early-stage academic founders who are ready to take on a director or ownership role of a developing business.

PhenUtest continues to go from strength-to-strength

The University of Liverpool spin-out company PhenUtest continues to build on their accomplishments

New University spin-out Sulantrix targeting untapped pseudoenzymes for new cancer medicines

A new University of Liverpool spin-out drug discovery company, Sulantrix, is exploring new medicines targeting cancer

New spin-out to deploy novel AI solution to reduce vision loss for people with diabetes

AI Sight will commercialise a next generation artificial intelligence (AI) system that will revolutionise diabetic eye screening

Tandem Nano and Medicines Patent Pool

Tandem Nano has signed a licence agreement with The Medicines Patent Pool (MPP) focused on the development of proprietary long-acting therapeutic technologies.

Meta Additive

University spin-out company, Meta Additive, acquired by Desktop Metal
Interview with Donna Bradshaw

Interview with Donna Bradshaw

Donna Bradshaw joined the University of Liverpool’s IP Commercialisation team as the first Entrepreneur Coach in Residence 2023.

Liverpool Chirochem secures £2.25m investment funding

The international chemical technology business began in the University’s Chemistry department

Success for University of Liverpool entrepreneurs at Educate North Awards 2023

Two entrepreneurs from the University of Liverpool named as 2023 winners.

Combatting AMR through research commercialisation

Dr Srijan Jindal is tackling global AMR with rapid, point-of-care diagnostics through innovation and creative thinking in the Liverpool City Region and across the globe.
Enterprise and Entrepreneurship

Enterprise and Entrepreneurship - a year of success

Read about our Research Commercialisation achievements and growing spin-out portfolio in our Enterprise and Entrepreneurship 2021-22 report.